|
|
News for Healthier Living
FDA Approval Opens New Chapter in Pancreatic Cancer Treatment
FDA Approval of Rasonque (daraxonrasib), represents a monumental shift in the treatment of pancreas cancer and demonstrates that RAS, one of the most important drivers of pancreatic cancer, can be successfully targeted.
August 27, 2026
September 1 2026August 31 2026August 30 2026August 29 2026August 28 2026August 27 2026August 26 2026August 25 2026August 24 2026August 21 2026August 20 2026August 19 2026August 18 2026
|
|
|
|
|